{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-000832","form_type":"8-K","ticker":"IMCR","cik":"0001671927","company_name":"Immunocore Holdings plc","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.054779+00:00","generated_at":"2026-06-07T03:09:39.570758+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunocore strategic update: KIMMTRAK expansion, PRAME Phase 3 start, new autoimmune candidates","bullets":["Preliminary cash and cash equivalents ~$443M as of Dec 31, 2023.","KIMMTRAK expansion: TEBE-AM (2L+ cutaneous melanoma) Phase 2 data Q4 2024; ATOM (adjuvant uveal melanoma) Phase 3 start 2H 2024.","PRAME franchise: PRISM-MEL-301 Phase 3 in 1L cutaneous melanoma to begin randomization Q1 2024; Phase 1/2 data across melanoma, ovarian, NSCLC expected in 2024.","New candidates: IMC-R117C (PIWIL1) for GI cancers; two autoimmune candidates for type 1 diabetes and dermatology.","HIV candidate IMC-M113V Phase 1 MAD data expected 2H 2024; HBV trial amended to include HCC."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-000832","json":"https://secwatch.observer/filing/0001140361-24-000832.json","markdown":"https://secwatch.observer/filing/0001140361-24-000832.md","text":"https://secwatch.observer/filing/0001140361-24-000832.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124000832/0001140361-24-000832-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124000832/ef20018111_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:09:39.570758+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}